From the Department of Nephrology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
ASAIO J. 2022 Mar 1;68(3):402-406. doi: 10.1097/MAT.0000000000001531.
This study aimed to effectively control the disease process of hemodialysis outpatients. Hemodialysis secondary hyperparathyroidism patients were randomly divided into the control group and treatment group. The control group was treated with routine treatment, and the treatment group was treated with sodium thiosulfate based on the control group. The changes of serum calcium, phosphorus, whole parathyroid hormone, calcium-phosphorus product and coronary artery calcification (CAC) score, as well as the relief of clinical symptoms, postoperative complications and recurrence in the preoperative and postoperative periods were observed. The levels of C-reactive protein and CAC scores were significantly decreased in the treatment group after treatment. While there was no significant difference in blood calcium, blood phosphorus, PTH, calcium-phosphorus product, and CAC score in the control group after treatment. And after treatment, the proportion of skin pruritus, myasthenia, bone pain, insomnia, restless legs syndrome, and other symptoms in the treatment group was significantly decreased compared with those before treatment, but there was no significant change in the control group before and after treatment. Sodium thiosulfate can reduce the high level of CAC in hemodialysis patients obviously.
本研究旨在有效控制血液透析门诊患者的疾病进程。将继发性甲状旁腺功能亢进的血液透析患者随机分为对照组和治疗组。对照组采用常规治疗，治疗组在对照组的基础上采用硫代硫酸钠治疗。观察两组患者血清钙、磷、全甲状旁腺激素、钙磷乘积及冠状动脉钙化（CAC）评分的变化，以及临床症状缓解、术后并发症及复发情况。治疗后治疗组 C 反应蛋白和 CAC 评分水平明显降低，而对照组治疗后血钙、血磷、PTH、钙磷乘积和 CAC 评分无明显差异。治疗后治疗组皮肤瘙痒、肌无力、骨痛、失眠、不宁腿综合征等症状的比例明显低于治疗前，而对照组治疗前后无明显变化。硫代硫酸钠能明显降低血液透析患者 CAC 水平升高。
